diabetes mellitus/seizures

FIELD This disclosure relates to an innovative and path-breaking technique that treats Diabetes mellitus and to obtain optimum glycemic control in type I and type II diabetic patients. The disclosure also provides an eco-friendly method and manner of extracting the plant Costus pictus D. Don. Syn:

FIELD This disclosure relates to an innovative and path-breaking technique that treats Diabetes mellitus and to obtain optimum glycemic control in type I and type II diabetic patients. The disclosure also provides an eco-friendly method and manner of extracting the plant Costus pictus D. Don. Syn:

FIELD This disclosure relates to an innovative and path-breaking technique that treats Diabetes mellitus and to obtain optimum glycemic control in type I and type II diabetic patients. The disclosure also provides an eco-friendly method and manner of extracting the plant Costus pictus D.Don. Syn:

FIELD This disclosure relates to an innovative and path-breaking technique that treats Diabetes mellitus and to obtain optimum glycemic control in type I and type II diabetic patients. The disclosure also provides an eco-friendly method and manner of extracting the plant Costus pictus D.Don. Syn:

RELATED APPLICATIONS This Application claims priority from co-pending PCT Application Ser. No. PCT/IN2004/000019, filed Jan. 28, 2004, which is incorporated in its entirety by reference. FIELD This disclosure relates to an innovative and path-breaking technique that treats Diabetes mellitus and to

FIELD This disclosure relates to an innovative and path-breaking technique that treats Diabetes mellitus and to obtain optimum glycemic control in type I and type II diabetic patients. The disclosure also provides an ecofriendly method and manner of extracting the plant Costus pictus D. Don. Syn:

BACKGROUND OF THE INVENTION The invention relates to a method of using tetracycline compounds in the treatment of diabetes. Specifically, the invention relates to a therapeutic method of using tetracyclines in managing patients suffering from pathological conditions associated with diabetes

BACKGROUND OF THE INVENTION Pursuant to 37 C.F.R. 1.821(c), a sequence listing is submitted herewith as an ASCII compliant text file named "MESCP0071USC1_ST25.txt", created on Dec. 5, 2017 and having a size of .about.3 kilobytes. The content of the aforementioned file is hereby incorporated by

The sequence listing that is contained in the file named "MESCP0071US_ST25.txt", which is 3 KB (as measured in Microsoft Windows.RTM.) and was created on Apr. 30, 2015, is filed herewith by electronic submission and is incorporated by reference herein. BACKGROUND OF THE INVENTION 1. Field of the

CROSS REFERENCE TO RELATED APPLICATIONS This application is a National Stage of International Application No. PCT/JP2012/081744 filed Dec. 7, 2012, claiming priority based on Japanese Patent Application No. 2011-268561 filed Dec. 8, 2011, the contents of all of which are incorporated herein by

CROSS REFERENCE TO RELATED APPLICATIONS This application is a national phase of International Application No. PCT/US2014/027450 filed on Mar. 14, 2014, which claims the benefit of U.S. Provisional Application No. 61/785,478 filed on Mar. 14, 2013, each of which are incorporated herein by reference

The present invention relates to certain novel substituted dihydroimidazo[2,1-b]thiazole and dihydro-5H-thiazolo[3,2-a]pyrimidine compounds which have affinity for 5-HT.sub.1A receptors and which inhibit neuronal reuptake of 5-hydroxytryptamine and/or noradrenaline, to processes for their

CROSS REFERENCE TO RELATED APPLICATION The present invention is based on, and claims priority from 60/008,390, filed Dec. 8, 1995. BACKGROUND OF THE INVENTION This application is directed to inhibitors of nitric oxide synthase, and in particular substituted azacycle derivatives. Nitric Oxide in

BACKGROUND OF THE INVENTION This application is directed to inhibitors of Nitric oxide synthase, and in particular cyclic amidines. Nitric Oxide in Biology. The emergence of nitric oxide (NO), a reactive, inorganic radical gas as a molecule contributing to important physiological and pathological

CROSS-REFERENCE TO RELATED APPLICATIONS Not Applicable STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT Not Applicable REFERENCE TO A COMPUTER PROGRAM APPENDIX Not Applicable INCORPORATION BY REFERENCE The following publications which are identified herein using a number inside